Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cassiopea in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $35.15.
Current Consensus is
The current consensus among 0 polled investment analysts is to n/a stock in Cassiopea. This rating has held steady since March 2021, when it changed from a Buy consensus rating.
Cassiopea SpA is a clinical-stage specialty pharmaceutical company. It engages in developing and commercializing and medical dermatology products focusing on the topical treatment of acne, androgenic alopecia, and genital warts. The firm's products include Winlevi, Breezula, Clascoterone Solution, CB-06-02, and CB-06-01. The company was founded on July 30, 2013 and is headquartered in Milan, Italy.